1. Home
  2. LFST vs LQDA Comparison

LFST vs LQDA Comparison

Compare LFST & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeStance Health Group Inc.

LFST

LifeStance Health Group Inc.

HOLD

Current Price

$7.28

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$37.31

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFST
LQDA
Founded
2015
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
LFST
LQDA
Price
$7.28
$37.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
10
Target Price
$8.83
$38.60
AVG Volume (30 Days)
2.0M
1.9M
Earning Date
02-26-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,367,570,000.00
$69,216,000.00
Revenue This Year
$15.83
$1,005.03
Revenue Next Year
$14.29
$204.13
P/E Ratio
N/A
N/A
Revenue Growth
13.39
343.41
52 Week Low
$3.74
$11.26
52 Week High
$8.30
$41.57

Technical Indicators

Market Signals
Indicator
LFST
LQDA
Relative Strength Index (RSI) 59.09 60.22
Support Level $7.09 $29.41
Resistance Level $7.48 $41.57
Average True Range (ATR) 0.22 3.03
MACD -0.02 0.43
Stochastic Oscillator 66.23 68.38

Price Performance

Historical Comparison
LFST
LQDA

About LFST LifeStance Health Group Inc.

LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: